BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brandse JF, Peters CP, Gecse KB, Eshuis EJ, Jansen JM, Tuynman HA, Löwenberg M, Ponsioen CY, van den Brink GR, Dʼhaens GR. Effects of Infliximab Retreatment After Consecutive Discontinuation of Infliximab and Adalimumab in Refractory Crohnʼs Disease: . Inflammatory Bowel Diseases 2014;20:251-8. [DOI: 10.1097/01.mib.0000438248.14218.1d] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Lelli F, Nuhoho S, Lee XY, Xu W. Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn's disease in Europe. Clin Exp Gastroenterol 2016;9:311-23. [PMID: 27785086 DOI: 10.2147/CEG.S109696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Asada T, Nakayama G, Tanaka C, Kobayashi D, Ezaka K, Hattori N, Kanda M, Yamada S, Koike M, Kodera Y. Postoperative adalimumab maintenance therapy for Japanese patients with Crohn's disease: a single-center, single-arm phase II trial (CCOG-1107 study). Surg Today 2018;48:609-17. [PMID: 29476258 DOI: 10.1007/s00595-018-1634-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Hughes JT, Herfarth HH, Isaacs KL, Plevy SE, Sartor RB, Sheikh SZ, Hansen JJ, Long MD. Infliximab Re-treatment in Inflammatory Bowel Disease: A Single-Center Routine Clinical Experience. Clin Gastroenterol Hepatol 2015;13:1704-5. [PMID: 24835819 DOI: 10.1016/j.cgh.2014.05.007] [Reference Citation Analysis]
4 de Boer NKh, Löwenberg M, Hoentjen F. Management of Crohn's disease in poor responders to adalimumab. Clin Exp Gastroenterol 2014;7:83-92. [PMID: 24748811 DOI: 10.2147/CEG.S47627] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Yang S, Yang S, Kwon Jo Y, Kim S, Jung Chang M, Choi J, Hee Cheon J, Yu YM. Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis. Ther Adv Chronic Dis 2021;12:20406223211041927. [PMID: 34729142 DOI: 10.1177/20406223211041927] [Reference Citation Analysis]
6 Deepak P, Bruining DH. Update on the Medical Management of Crohn's Disease. Curr Gastroenterol Rep 2015;17:41. [PMID: 26363802 DOI: 10.1007/s11894-015-0465-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
7 Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, Ben-Horin S, Chen MH. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease. J Gastroenterol 2017;52:535-54. [PMID: 28275925 DOI: 10.1007/s00535-017-1324-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 12.2] [Reference Citation Analysis]